[1]赵丹 周鹏.达比加群及其逆转剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):801-804.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
　ZHAO DanZHOU Peng.Dabigatran and Reversal in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):801-804.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
点击复制

达比加群及其逆转剂在心血管疾病中的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年5期
页码:
801-804
栏目:
综述
出版日期:
2019-08-25

文章信息/Info

Title:
Dabigatran and Reversal in Cardiovascular Diseases
作者:
赵丹 周鹏
(成都医学院第一附属医院心血管内科,四川 成都 610500)
Author(s):
ZHAO DanZHOU Peng
(Department of CardiologyThe First Affiliated Hospital of Chengdu Medical CollegeChengdu 610500SichuanChina)
关键词:
达比加群; 心房颤动; 冠状动脉粥样硬化性心脏病; 静脉血栓; 依达赛珠单抗
Keywords:
Dabigatran; Atrial Fibrillation; Coronary Heart Disease; Venous thrombosis; Idarucizumab
DOI:
10.16806/j.cnki.issn.1004-3934.2019.05.034
摘要:
新型口服抗凝药通过抑制凝血酶促反应中特定凝血因子的途径预防和治疗血栓，包括凝血酶抑制剂(达比加群)和凝血因子Ⅹa抑制剂（利伐沙班、阿哌沙班、依杜沙班等），主要用于非瓣膜性心房颤动、肺栓塞和关节置换术后深静脉血栓的预防和治疗等。达比加群可产生有效、可预测、稳定的抗凝效果，且较少与药物食物发生相互作用，无需常规进行凝血功能监测及剂量调整，临床应用更加方便。随着依达赛珠单抗的获批，达比加群成为第一种拥有特异性逆转剂的新型口服抗凝药，标志着抗凝治疗进入了一个新阶段。现将达比加群酯的药物作用机制、药物相互作用、在心血管疾病中的研究进展及其逆转剂做一简要综述。
Abstract:
New oral anticoagulants inhibit blood coagulation pathways in particular of the clotting factors,for example thrombin inhibitors (dabigatran etexilate)and blood coagulation factor X inhibitors (rivaroxaban,apixaban,edoxaban,etc.). It is mainly used for the prevention and treatment of non-valvular atrial fibrillation, pulmonary embolism and deep venous thrombosis after joint replacement. Dabigatran has the characteristics of rapid onset, no need to frequently monitor coagulation function, and is more convenient for clinical application. With the approval of Idarucizumab, dabigatran became the first new oral anticoagulants with a specific reversal agent, marking a new stage in anticoagulant therapy. The drug mechanism of action of dabigatran etexilate, drug interactions, its application in cardiovascular diseases and its reversal agents are now briefly reviewed

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
　HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(5):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
　DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(5):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
　ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
　ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
　HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
　WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
　XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
　ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
　WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
　ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金项目（81641058）；国家临床重点专科建设培育科室专项科研项目（CYFY2017GLPX01）；四川省科技厅应用基础研究计划项目（2015JY0275）
更新日期/Last Update: 2019-12-25